Berenberg lifts target for Qiagen stock to EUR 46.50

Published on 10/27/2026 at 16:55 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Next results are due November 4, 2026. Qiagen stock costs EUR 45.16 on October 27, 2026, plus 0.13 percent versus the October 26 Xetra close.

Analyst target and reporting date

Berenberg raised its Qiagen target from EUR 40.00 to EUR 46.50 on October 22, 2026.
Qiagen plans to report full third-quarter results on November 4, 2026.
Qiagen stock costs EUR 45.16 at Lang & Schwarz on October 27, 2026, plus 0.13 percent versus the Xetra close of October 26, 2026.
Preliminary third-quarter sales reached USD 548.00 million, while adjusted diluted earnings per share were USD 0.65.

Qiagen, NL0015002SN0, Illustration mit AI erstellt.

Qiagen (NL0015002SN0) received a higher EUR 46.50 price target from Berenberg, up from EUR 40.00 in the firm's October 22, 2026 research note, as reported by MarketScreener. The stock was trading at EUR 45.16 at Lang & Schwarz on October 27, 2026 at 4:44 p.m. CET, plus 0.13 percent versus the Xetra close of October 26, 2026 at EUR 45.10.

Target leaves limited upside

The revised target is 16.25 percent above Berenberg's previous EUR 40.00 target. At EUR 45.16, the new target stands 2.97 percent above the euro price, keeping the analyst view close to the current quotation rather than signaling a wide valuation gap.

Primary listing stays below yearly high

On the Nasdaq, Qiagen was last at USD 50.33 on October 27, 2026 at 11:53 a.m. ET. The price stood 12.96 percent below its USD 57.82 52-week high and 54.72 percent above its USD 32.53 low. The primary-market snapshot showed a USD 10.4 billion market capitalization and a trailing P/E ratio of 25.81.

November 4 sets the next date

QIAGEN reported preliminary third-quarter 2026 net sales of USD 548.00 million and adjusted diluted earnings per share of USD 0.65 in its October 21, 2026 release. The full results are scheduled for November 4, 2026, according to QIAGEN.

Comparison with peers

Qiagen: plus 0.13 percent versus the Xetra close, P/E 25.81, market capitalization USD 10.4 billion as of October 27, 2026.

Thermo Fisher Scientific (NYSE, USD): plus 1.58 percent, P/E 36.66, market capitalization USD 257.2 billion as of October 27, 2026.

Danaher (NYSE, USD): minus 0.19 percent, P/E 38.04, market capitalization USD 163.5 billion as of October 27, 2026.

Qiagen stock stays near the offer level

The analyst target, the scheduled results date and the preliminary quarterly figures give investors three concrete reference points for the next trading phase. The latest euro quotation remains only EUR 0.06 above the October 26 Xetra close.

The further course of trading is shown by the continuously updated real-time quote of Qiagen stock.